The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | A novel agent BI-1206 in combination with rituximab in indolent NHL
Mariana Bastos, MD, PhD, Gregorio Marañón University General Hospital, Madrid, Spain, discusses the novel agent BI-1206, which has shown encouraging results in combination with rituximab for the treatment of indolent non-Hodgkin lymphoma (NHL). She highlights that the next step is to investigate BI-1206 in combination with BTK inhibitors. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Abbvie, Astra-Zeneca, BMS/Celgene, Incyte, Kite, Novartis, Roche, Takeda; Research Funding: Roche, Kite, AMHH, SEHH, IiCIII; Honoraria: Abbvie, BMS/Celgene, Incyte, Kite, Novartis, Roche, Takeda.
